Priprava kompleksa etorikoksiba s β-ciklodekstrinom metodom gnječenja i njihova karakterizacija by HARESH M. PATEL et al.
Etoricoxib (ET), 5-chloro-6’-methyl-3-[4-(methylsulfonyl)phenyl]-2,3’-bipyridine, a
novel highly selective COX-2 inhibitor, is used for a variety of acute and chromic inflam-
matory diseases (1). However, its very low aqueous solubility and poor dissolution can
cause formulation problems and limit its therapeutic application by delaying the rate of
absorption and the onset of action (2). Solid dispersions of etoricoxib are reported with
lipid carrier and polymers for improving dissolution (3, 4) Cyclodextrins are commonly
used in drug formulations as solubility enhancers because of their ability to form water
soluble inclusion complexes with poorly water soluble drugs (5, 6). Various anti-inflam-
matory drugs have been complexed with cyclodextrins, thus obtaining further advan-
tages such as dose lowering, reduction of side effects (particularly gastric irritation) and
taste masking (7, 8). The method of complexation may play a role in drug solubilization
(9). Therefore, it seemed of interest to extend our investigations to a series of binary sys-
tems of etoricoxib with  -cyclodextrin.
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The binary system of etoricoxib with b-cyklodextrin (b-CD)
was prepared by the kneading method. Drug-cyclodex-
trin interactions in solution were investigated by the phase
solubility analysis. Differential scanning calorimetry, in-
frared spectroscopy, powder X-ray diffractometry and
microscopic study were used to characterize the solid state
of all binary systems, whereas their dissolution proper-
ties were evaluated according to the USP XXIII paddle me-
thod. The results indicate partial interaction of the drug
with b-CD in the physical mixture and complete interac-
tion in the kneaded complex. The dissolution of etorico-
xib was notably increased as compared to pure drug as
well as its physical mixture. The complex showed more
than 75% drug released in 30 min.
Keywords: etoricoxib, cyclodextrin, complexation, knead-
ing method
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EXPERIMENTAL
Materials
Etoricoxib working standard was procured as a gift sample from Sun Pharmaceutical
Industries Ltd., India.  -cyclodextrin (b-CD) was procured as a gift sample from Cadila
Pharmaceuticals Ltd., India. Methanol and potassium dihydrogen orthophosphate were
purchased from S. D. Fine Chem. Pvt. Ltd., India.
Phase solubility studies
An excess of drug was added to 10 mL of water or  -CD aqueous solutions (3–20
mmol L–1) in 25-mL stoppered conical flasks and shaken at room temperature on a mag-
netic stirrer (10). At equilibrium after 2 days, aliquots were withdrawn, filtered (0.22 µm
pore size, Whatman UK) and spectrophotometrically assayed for drug content at 284.0
nm (Shimadzu UV- 160A Spectrophotometer, Shimadzu, Japan). The apparent 1:1 stabili-
ty constant of the etoricoxib-cyclodextrin complex was calculated from the phase-solu-
bility diagram:
Kc = (slope/S0) x (1 – slope)
where Kc is the stability constant (L mol–1), slope is obtained from the linear relationship be-
tween the concentration of etoricoxib and b-CD and S0 is etoricoxib solubility (mmol–1 L).
Each experiment was carried out in triplicate (RSD < 3%).
Preparation of physical mixtures and the solid inclusion complex
For physical mixtures, ET and  -cyclodextrin were weighed accurately at a 1:1 mo-
lar ratio, mixed thoroughly by trituration in a mortar and sieved through 0.25 mm sieve.
All physical mixtures were stored in dessicator until further evaluation.
The inclusion complex of etoricoxib with  -CD was prepared at a 1:1 molar ratio by
wetting the physical mixture in a mortar with a minimum volume of ethanol/water (1:1,
by volume) mixture and kneading thoroughly with a pestle to obtain a paste, which was
then dried under vacuum at room temperature, sieved through 0.25 mm sieve and stor-
ed in a dessicator until further evaluation.
Inclusion efficiency
The kneaded complex and its physical mixtures (25 mg) were placed in 25-mL volu-
metric flasks. Methanol (10 mL) was added, mixed thoroughly and sonicated for 30 min.
The volume was made up to the mark with methanol. The solution was suitably diluted
with the same solvent and spectrophotometrically assayed for drug content at 284.0 nm.
Etoricoxib content was calculated as above.
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Dissolution studies
Dissolution studies were performed in phosphate buffer (pH 7.4, 900 mL) at 37 ± 0.2 °C,
using USP XXIII apparatus (Electrolab, India) with a paddle rotating at 50 rpm (11). So-
lid products, each containing 60 mg of drug, were subjected to dissolution. At fixed time
intervals, withdrawn samples were filtered (Whatman filter paper No. 41) and spectro-
photometrically assayed for drug content at 284.0 nm. Dissolution efficiency (DE) was
calculated from the area under the dissolution curve at time t (measured using the trape-
zoidal rule) and expressed as percentage of the area of the rectangle described by 100%
dissolution in the same time (12).
Differential scanning calorimetry (DSC)
DSC analysis was performed using DSC (Model DT-60, Shimadzu). Samples (Shi-
madzu libror AEG 220 electronic balance, 5–7-mg) were heated in open aluminium pans at
a rate of 10 °C min–1 in a 0–300 °C temperature range under a nitrogen steam. The instru-
ment was calibrated using indium (melting point, 156.61 °C; enthalpy of fusion, 28.71 J g–1).
X-ray powder diffractometry (XRPD)
X-ray powder diffraction patterns were recorded on an X-ray diffractometer (Model
X”Pert, Philips, the Netherlands) using Ni-filtered, Cu K radiation, voltage of 40 kV
and 25 mA current. The scanning rate employed was 1° min–1 over the 0–100° diffraction
angle (2q) range.
Fourier transform infrared (FTIR) spectroscopy
FTIR spectra were recorded on samples prepared in KBr using FTIR-8400S with IR
solution software (Shimadzu). Data were collected over a spectral region from 4000 to
650 cm–1 with resolution 4 cm–1 and 100 scans.
RESULTS AND DISCUSSION
Preliminary studies
The complexation of etoricoxib with b-CD was studied at molar ratios of 1:0.5, 1:1.0,
1:1.5, 1:2.0, 1:2.5, and 1:3.0. The complexes were prepared by the kneading method and
were characterized by inclusion efficiency, dissolution, wettability and HPTLC studies.
All complexes showed increased dissolution efficiency, reduced time required for 50%
drug to be dissolved and improved wettability (less wetting time, 76–45 min, compared
to pure drug) and almost constant inclusion efficiency. HPTLC of the complex suggested
only one component in prepared systems (data not shown).
Higher dissolution (> 75% released in 30 min) was obtained using a 1:1 molar ratio
of the drug to b-CD. Therefore further investigations were carried out for the 1:1 molar
ratio.
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Phase solubility
Etoricoxib is a sparingly soluble drug. The solubility of etoricoxib in distilled water
at pH 6.8 at room temperature was 24.0 µg mL–1 and was notably affected by the pres-
ence of b-CD. Solubility of ET in 4 mmol L–1 b-CD aqueous solution was 0.025 mmol L–1
while it was 0.045 mmol L–1 in 20 mmol L–1 b-CD solution. The obtained phase solubili-
ty diagram was linear (Fig. 1) and could be classified as AL type according to Higuchi
and Connors (10). The slope of solubility diagram was less than one; it was therefore as-
sumed that the solubility increase could be attributed to the formation of the 1:1 com-
plex.
Stability constant value obtained for the etoricoxib-CD complex was 170.13 L mol–1,
which indicated that the etoricoxib-b-cyclodextrin complex at a 1:1 ratio is adequately
stable (10).
Inclusion efficiency
The percentage of etoricoxib in the samples ranged from 98.2 ± 0.2 to 100.2 ± 0.1
(n = 3), as reported in Table I. This indicated that etoricoxib was uniformly distributed in
all the samples.
Dissolution
The in vitro dissolution profiles of the drug, physical mixture and inclusion complex
are shown in Fig. 2. The dissolution of complexes was higher compared to the drug alone.
The dissolution profile of the kneaded complex (1:1 molar ratio showed 80.0% drug re-
leased in 30 min while that of the 1:1 physical mixture and pure drug showed 50.8% and
40.7%, respectively. This enhancement can be attributed to the higher hydrophilic char-
acter of the systems due to the presence of the carrier, which can reduce the interfacial
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Fig. 1. Phase solubility diagram of etoricoxib in 3–15 mmol L–1 b-cyclodextrin aqueous solution
(mean ± SD, n = 3). Linear equation is y = 0.0041x + 0.0547) (R = 0.9988).
tension between the poorly water soluble drug and the dissolution medium (14). More-
over, in the case of b-CD, in the early stage of the dissolution process, the carrier dis-
solves more rapidly than the drug. Hence, it can act on the hydrodynamic layer sur-
rounding the drug particles, resulting in an in situ inclusion process that improves the
dissolution of the drug (14). In fact, the systems containing a larger amount of b-CD
showed faster drug dissolution. It must be pointed out that the 1:1 kneaded complex
showed improved drug dissolution compared to its physical mixture. As shown above,
the kneaded complex showed 1.6 time higher dissolution in 30 min than the physical
mixture.
DE values and the time taken for 50% dissolution (t50) based on the dissolution data
were calculated according to the Khan method (12) (Table I). Also, all the complexes of
ET with b-CD exhibited higher DE120 values (DE for 120 min) than ET itself and its phy-
sical mixture, namely 77.9 vs. 62.7 and 47.3% respectively. Therfore, the 1:1 kneaded
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Drug 100.2 ± 0.1 47.3 ± 1.0 59.9 ± 2.4 149.0 ± 1.0
1:1 kneaded complex 98.2 ± 0.2 77.9 ± 0.3 3.7 ± 0.0 69.5 ± 1.0
1:1 physical mixture 99.5 ± 0.2 62.7 ± 0.7 7.2 ± 0.1 73.5 ± 1.0

























Fig. 2. Dissolution profile of etorico-
xib and its preparations (mean ± SD,
n = 3).
complex and 1:1 physical mixture showed 1.7 and 1.3 times higher dissolutions efficien-
cy compared to pure drug in 120 min. The DE120 values increased as the proportion of
b-CD in complexes was increased.
DSC
DSC curves of the pure drug, b-CD, 1:1 molar physical mixture and 1:1 molar knead-
ed complex are shown in Fig. 3. DSC curve of the drug showed a sharp endothermic
peak at 140.68 °C corresponding to the melting point of etoricoxib. DSC curve of b-CD
showed a slightly sharp endothermic peak at 148.59 °C corresponding to the melting po-
int of b-CD. DSC curve of the 1:1 molar ratio physical mixture of the drug and b-CD
showed two broad endothermic peaks, one broad peak at 130.74 °C corresponding to
etoricoxib and another broad peak at 139.18 °C corresponding to b-CD. DSC curve of the
1:1 molar ratio kneaded complex of the drug and b-CD showed two broad endothermic
peaks, one broad peak at 133.20 °C corresponding to etoricoxib and another broad peak at
150.99 °C corresponding to b-CD. Peak temperatures in the physical mixture and kneaded
complex were slightly shifted with respect to the drug alone.
The DH values of the drug, b-CD, physical mixture and its complex were found to
be –88.52, –78.74, –40.27 and –22.45 J g–1, respectively. The reduction of the kneaded com-
plex DH value compared to the pure drug and physical mixture could be attributed to
the amorphous form of the drug in the complex.
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Fig. 3. DSC thermograms of: a) drug, b) b-CD, c) 1:1 physical mixture and d) 1:1 kneaded complex.
XRPD
The X-ray diffraction patterns of the drug, 1:1 physical mixture and 1:1 kneaded com-
plex are presented in Fig. 4. Characteristic peaks appeared in the XRPD pattern of the
drug alone, suggesting that the drug is present as a crystalline material. All the peaks of
etoricoxib in the complex showed lower intensity compared to the pure drug and physi-
cal mixture. This result indicated that the drug in the complex is completely amorphous
compared to the pure drug as well as physical mixture.
FTIR
The FTIR spectra of pure etoricoxib showed characteristic peaks at 1598.9 cm–1 (C=N
stretching vibration), 1433.0, 1300.0, 1130.2 and 1083.9 cm–1 (S=O stretching vibration)
and 839.0, 781.1 and 638.0 cm–1 (C–Cl stretching vibration). The spectrum of pure b-CD
showed characteristic peaks at 3290.3 and 3230.5 cm–1. The spectrum of the physical
mixture is exactly matched with the b-CD spectra and the crystalline drug spectrum. This
indicated that no interaction occurred during simple physical mixing of the drug and
b-CD. The complexes of etoricoxib with b-CD revealed a shift and slight broadening of
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Fig. 4. XRD of: a) drug, b) 1:1 physical mixture and c) 1:1 kneaded complex.
S=O stretching vibration (1080.1 cm–1) peak of etoricoxib and O–H stretching vibration
peaks (3344.3 and 3290.3 cm–1) characteristic of the carrier. These observations might in-
dicate the possibility of intermolecular hydrogen bonding via the S=O group of etorico-
xib and OH group of b-CD.
Wettability
The wetting time (13) for the drug, its physical mixture and its complex is presented
in Table I. The wetting time of the drug was found to be 149.0 min while that of the com-
plex (1:1 molar ratio) was found to be 69.5 min. These observations might indicate that
the drug in systems was more hydrophilic and more easily wettable compared to pure
drug in the dissolution medium. Increased wetting of the particles may be considered to
be a major contributor to the enhanced etoricoxib dissolution from the complex system
containing b-CD.
CONCLUSIONS
The dissolution profile of the kneaded complex (1:1 molar ratio) showed more than
75% drug released in 30 min. Further study is required to prepare a prompt release oral
formulation of etoricoxib by utilizing this complex.
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S A @ E T A K
Priprava kompleksa etorikoksiba s b-ciklodekstrinom metodom
gnje~enja i njihova karakterizacija
HARESH M. PATEL, BHANUBHAI N. SUHAGIA, SHAILESH A. SHAH, ISHWAR SINH RATHOD i VIJAY K. PARMAR
Metodom gnje~enja pripravljen je binarni sustav etorikoksiba s b-ciklodekstrinom
(b-CD). Tijekom 30 minuta iz kompleksa se oslobodilo vi{e od 75% ljekovite tvari, {to je
zna~ajno vi{e u odnosu na fizi~ku smjesu etorikoksiba i b-CD ili ~istu ljekovitu tvar. In-
terakcije lijeka i ciklodekstrina u otopini ispitivane su analizom fazne topljivosti. Za ka-
rakterizaciju ~vrstog stanja svih binarnih sustava kori{tena je diferencijalna pretra`na kalo-
rimetrija, infracrvena spektroskopija, difrakcija rentgenskih zraka na pra{kastom uzorku
i mikroskopija. Osloba|anje je pra}eno metodom lopatice prema USP XXIII. Rezultati
ukazuju na djelomi~nu interakciju ljekovite tvari s b-CD u fizi~koj smjesi te potpunu
interakciju u kompleksu.
Klju~ne rije~i: etorikoksib, ciklodekstrin, kompleksacija, metoda gnje~enja
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